EPZM / Epizyme Inc - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

EPZM / Epizyme Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* Epizyme, Inc. (Name of Issuer) COM (Title of Class of Securities) 29428V104 (CUSIP Number) August 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35945 Epizyme, Inc. (Exact name of registrant as specified in its charte

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

S-8 POS 1 d371530ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos. 333-266521 333-263164 333-253383 333-236707 333-229878 333-223612 333-216638 333-210028 333-202681 333-194205 333-189629 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-266521

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.

EPZM / Epizyme Inc / Ipsen, S.a. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EPIZYME, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29428V104 (CUSIP Number) Francois Garnier, EVP General Counsel and Chief Business Officer Ipsen Pharma SAS 65 Quai Georges Gorse 92100 Boulogne-Bill

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration Nos.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) EPIZYME, INC. (Name of Subject Company (Issuer)) HI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) EPIZYME, INC. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) EPIZYME, INC. (Name of Subject Company) EPIZYME, INC. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29428V104 (CUSIP Nu

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35945 26-1349956 (State or Other jurisdiction of Incorporation) (Commission File Numb

Sixth Amended and Restated Certificate of Incorporation of the Company

Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EPIZYME, INC. Article 1: The name of the corporation is Epizyme, Inc. (the ?Corporation?). Article 2: The address of the Corporation?s registered office in the state of Delaware is 251 Little Falls Drive, Wilmington, DE 19808, New Castle County. The name of its registered agent at such address is Corporation Service Company. Ar

Second Amended and Restated Bylaws of the Company

Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF EPIZYME, INC. Article 1: Corporate Offices Section 1.1 Offices. In addition to the corporation?s registered office set forth in the certificate of incorporation, the Board of Directors may at any time establish other offices at any place or places where the corporation is qualified to do business. Article 2: Meetings of Stockholders Section 2.1 Pla

Consulting Agreement by and among Epizyme, Inc., BioStrategy, LLC, and Shefali Agarwal dated April 6, 2022 (1)

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is entered into as of April 6, 2022 by and among Epizyme, Inc. (the ?Company?), BioStrategy, L

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Stu

Exhibit 99.1 Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update TAZVERIK? (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company?s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 CAMBRIDGE, Mass.,

EPZM / Epizyme Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* Epizyme, Inc. (Name of Issuer) COM (Title of Class of Securities) 29428V104 (CUSIP Number) July 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X

Form of Option Agreement under the 2022 Equity Incentive Plan (1)

Exhibit 10.8 EPIZYME, INC. STOCK OPTION AGREEMENT Epizyme, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the Company?s Common Stock subj

Amendment No. 1 to License Agreement between the Company and HUTCHMED Group Investment Limited (formerly known as Hutchison China MediTech Investment Limited) (1)

Exhibit 10.2 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 1 TO LICENSE AGREEMENT THIS AMENDMENT No. 1 (this ?Amendment No. 1?) is made and entered into as of May 6, 2022 (?Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) EPIZYME, INC. (Name of Subject Company (Issuer)) HI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS

Press Release issued by Ipsen S.A. on August 5, 2022 announcing extension of the Offer.

Exhibit (a)(5)(D) Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 ? Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement ? Epizyme stockholders are encouraged to tender their shares to the offer today PARIS, FRANCE, 5 August 2022 ? Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) EPIZYME, INC. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) EPIZYME, INC. (Name of Subject Company) EPIZYME, INC. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29428V104 (CUSIP Nu

Restated Certificate of Incorporation, as amended of the Company (incorporated by reference to Exhibit 4.1 to Company’s Registration Statement on Form S-8 (File No. 333-266521) filed with the SEC on August 4, 2022)

Exhibit 4.1 RESTATED CERTIFICATE OF INCORPORATION OF EPIZYME, INC. Epizyme, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: That the name of the Corporation is Epizyme, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Epizyme, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) EPIZYME, INC. (Name of Subject Company (Issuer)) HI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS

EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, Massachusetts 02139 Tel: (617) 229-5872

Exhibit e(6) EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, Massachusetts 02139 Tel: (617) 229-5872 July 18, 2022 To holders of RSUs and/or options to purchase shares of Common Stock of Epizyme, Inc.: This letter (this ?Notice?) is to provide you notice of the pending acquisition (the ?Merger?) of Epizyme, Inc. (the ?Company?) by Ipsen Pharma SAS (the ?Parent?) and Hibernia Merger Sub,

Filing Fee table

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) EPIZYME, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) EPIZYME, INC. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) EPIZYME, INC. (Name of Subject Company) EPIZYME, INC. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29428V104 (CUSIP Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 EPIZYME, INC. (Name of Subject Company) EPIZYME,

SC 14D9 1 d738141dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 EPIZYME, INC. (Name of Subject Company) EPIZYME, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Cla

Mutual Confidentiality Agreement, effective as of February 7, 2022, by and between Epizyme and Ipsen.

Exhibit (d)(2) MUTUAL CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (?Agreement?) is entered into as of February 7, 2022 (?Effective Date?) by and between: Ipsen Pharma SAS, organized and existing under the laws of France, located at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France, represented by Jean-Patrick Hennebelle, VP Global Late Stage Partnering, duly authorized for the purposes of this Agreement (?Ipsen?), and Epizyme, Inc.

Exclusivity Letter Agreement, dated June 10, 2022, by and between Ipsen and Epizyme, as extended by letter agreement dated June 22, 2022.

Exhibit (d)(6) June 10, 2022 CONFIDENTIAL Ipsen Pharma SAS 65 Quai Georges Gorse 92100 Boulogne-Billancourt France Re: Exclusivity Agreement Dear Sir or Madam: This exclusivity agreement (the ?Exclusivity Agreement?) sets forth certain understandings between Ipsen Pharma SAS (?Buyer?) and Epizyme, Inc.

Notice of Guaranteed Delivery.

Exhibit (a)(1)(C) Notice of Guaranteed Delivery For Tender of Shares of Common Stock of EPIZYME, INC.

Offer to Purchase, dated July 12, 2022.

Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of EPIZYME, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS (Offeror) a wholly

Form of Summary Advertisement, published July 12, 2022 in the Wall Street Journal.

Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) EPIZYME, INC.

Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of EPIZYME, INC.

Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of EPIZYME, INC.

Form of Letter of Transmittal.

Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of EPIZYME, INC.

Severance and Change in Control Plan of the Company (as amended through May 25, 2022) (incorporated by reference to Exhibit (e)(5) to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 (File No. 005-87481) filed with the SEC on July 12, 2022)

Exhibit (e)(5) EPIZYME, INC. Severance and Change in Control Plan (as amended through May 25, 2022) Section I: Establishment and Purpose of Plan Epizyme, Inc. (the ?Company?) hereby establishes an unfunded Severance and Change in Control Plan (the ?Plan?), which is intended to be a welfare benefit plan within the meaning of Section 3(1) of the Employee Retirement Income Security Act of 1974, as am

JOINT FILING AGREEMENT

Exhibit 1.04 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement on Schedule 13D jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the complet

EPZM / Epizyme Inc / Ipsen, S.a. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. )* EPIZYME, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29428V104 (CUSIP Number) Francois Garnier, EVP General Counsel and Chief Business Officer Ipsen Pharma SAS 65 Quai Georges Gorse 92100 Boulogne-

Investor and analyst call Acquisition of Epizyme, Inc. 27 June 2022

Exhibit 99.1 Investor and analyst call Acquisition of Epizyme, Inc. 27 June 2022 Disclaimer and safe harbor?This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management?s current views and assumptions. Such statements involve known and u

Ipsen M&A/Other Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

Exhibit 99.2 Ipsen M&A/Other Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology Event Date: 06/27/2022 Company Name: Ipsen Event Description: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology Source: Ipsen Version: Final For more event information and transcripts, visit {IPN FP Equity EVT BB-5933748-1 } Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology Presentati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Offeror) a wholly owned subsidiary of IPSEN PHARMA SAS (Offeror) IPSEN S.

EPZM / Epizyme Inc / Rpi Finance Trust - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) George Lloyd, Esq. RP Management, LLC, 110 E. 59th Street, 33rd Floor New York, NY 10022 (212) 883-2280 (Name, Address and Telephone Number of Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB,

SC TO-C 1 d373557dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 EPIZYME, INC. (Name of Subject Company (Issuer)) HIBERNIA MERGER SUB, INC. (Offeror) a wholly owned subsidiary of IPSEN BIOPHARMACEUTICALS, INC. (Parent of Offeror) a wholly owned sub

Agreement and Plan of Merger, dated as of June 27, 2022, by and among Epizyme, Ipsen and Purchaser (incorporated herein by reference to Exhibit 2.1 to Form 8-K filed by Epizyme on June 27, 2022).

Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER by and among EPIZYME, INC., HIBERNIA MERGER SUB, INC. and IPSEN PHARMA SAS Dated as of June 27, 2022 TABLE OF CONTENTS Page Article I The Cash Tender Offer 2 1.1 The Offer 2 1.2 Company Actions 5 Article II The Merger 6 2.1 The Merger; No Vote of Stockholders 6 2.2 Effective Time of the Merger 6 2.3 Closing 6 2.4 Effects of the Merger 7 2.5 D

Form of Support Agreement by and among Ipsen, Purchaser and the stockholder named therein (incorporated herein by reference to Exhibit 2.2 to Form 8-K filed by Epizyme on June 27, 2022).

Exhibit 2.2 Final Form FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this ?Agreement?), dated as of June 27, 2022, is entered into by and among Ipsen Pharma SAS, a French soci?t? par actions simplifi?e (?Parent?), Hibernia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Ipsen Biopharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of the Parent (?

Joint Press Release, dated June 27, 2022

Exhibit 99.1 Disclaimer: Intended for international media and investor audiences only Ipsen to acquire Epizyme, expanding its portfolio in oncology ? Transaction focused on lead asset Tazverik? (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. ? Acquisition to bolster Ipsen?s growing oncology presence and leverage its infrastructure ? Ipsen to commence all-cash tender offer to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 EPIZYME, INC. (Name of Subject Company) EPIZYME,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 EPIZYME, INC. (Name of Subject Company) EPIZYME, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29428V104 (CUSIP Number of Class o

Email sent to employees of Epizyme on June 27, 2022 (incorporated herein by reference to Exhibit 99.2 to Epizyme’s Schedule 14D-9C filed on June 27, 2022).

Exhibit 99.2 Email from Grant Bogle to Epizyme, Inc. Employees Subject: Epizyme News | Ipsen to acquire Epizyme, expanding its portfolio in oncology Dear Epizymers, This morning, Ipsen and Epizyme jointly announced our decision to enter into a definitive merger agreement under which Ipsen will acquire Epizyme. Through this transaction, we will be acquired by Ipsen and they will be able to expand t

Corporate Statement for Use with Investors and Media dated June 27, 2022 (incorporated herein by reference to Exhibit 99.3 to Epizyme’s Schedule 14D-9C filed on June 27, 2022).

Exhibit 99.3 Ipsen Acquisition Standby Statement Standby Statement for Investor & Media Use As shared in today?s announcement, Ipsen and Epizyme have entered into a definitive merger agreement, under which Ipsen will acquire Epizyme. Through this transaction, we will be acquired by Ipsen and they will be able to expand their oncology footprint and capabilities by integrating our epigenetic experti

Form of Contingent Value Rights Agreement, by and between Purchaser and the Rights Agent (incorporated herein by reference to Exhibit 2.3 to Form 8-K filed by Epizyme on June 27, 2022).

Exhibit 2.3 Agreed Form FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of June 27, 2022 (this ?Agreement?), is entered into by and between Ipsen Pharma SAS, a French soci?t? par actions simplifi?e (?Parent?), and [?]1, as Rights Agent (the ?Rights Agent?). RECITALS WHEREAS, Parent, Hibernia Merger Sub, Inc., a Delaware corporation and a wholly-owned subs

Amendment to Amended and Restated By-laws of the Company, dated June 26, 2022

Exhibit 3.1 Amendment to Amended and Restated By-Laws of Epizyme, Inc. The Amended and Restated By-laws of Epizyme, Inc. be and hereby are amended by adding thereto a new Section 5.9 as follows: ?Section 5.9. Forum Selection By-law. Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of th

Disclaimer: Intended for international media and investor audiences only Ipsen to acquire Epizyme, expanding its portfolio in oncology

Exhibit 99.1 Disclaimer: Intended for international media and investor audiences only Ipsen to acquire Epizyme, expanding its portfolio in oncology ? Transaction focused on lead asset Tazverik? (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. ? Acquisition to bolster Ipsen?s growing oncology presence and leverage its infrastructure ? Ipsen to commence all-cash tender offer to

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2022 EPIZYME, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Epizyme, Inc. 2013 Employee Stock Purchase Plan, as amended and effective September 1, 2022

Exhibit 10.2 EPIZYME, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (as amended May 17, 2022; effective September 1, 2022) The purpose of this Plan is to provide eligible employees of Epizyme, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $0.0001 par value (the ?Common Stock?), commencing on August 1, 2013. Subject to adjustment

Epizyme, Inc. 2022 Equity Incentive Plan

Exhibit 10.1 EPIZYME, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2022 Equity Incentive Plan (the ?Plan?) of Epizyme, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing suc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 Firs

Exhibit 99.1 Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update TAZVERIK? (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme?s Phase 1b/3 Confirmatory Study Assessing Tazemetostat

Employment Offer Letter dated March 11, 2022 between the Registrant and Jerald Korn (1)

Exhibit 10.1 400 Technology Square, 4th Floor Cambridge, MA 02139 February 28, 2022 Mr. Jerald Korn Delivered via email Dear Jerald, I am pleased to offer you the position of Chief Operating Officer with Epizyme, Inc. reporting to Grant Bogle CEO. Salary You will receive a semi-monthly salary of $19,791.67, which is equivalent to $475,000 annually. It is understood and agreed that, as an integral

Executive Severance and Change in Control Plan, as amended (1)

Exhibit 10.2 EPIZYME, INC. Severance and Change in Control Plan (as amended through March 4, 2022) Section I: Establishment and Purpose of Plan Epizyme, Inc. (the ?Company?) hereby establishes an unfunded Severance and Change in Control Plan (the ?Plan?), which is intended to be a welfare benefit plan within the meaning of Section 3(1) of the Employee Retirement Income Security Act of 1974, as ame

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR f ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exa

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d312208ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study of

EX-99.1 Exhibit 99.1 Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 CAMBRIDGE, Mass., March 15, 2022 – Epizyme (Nasdaq: EPZM), a fully integrated, commercial-sta

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Consulting Agreement, dated October 1, 2021, by and between the Registrant and Victoria Vakiener (23)

Exhibit 10.43 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is entered into as of October 1, 2021 by and between Epizyme, Inc. (the ?Company?), and Victoria Vakiener (?Ms. Vakiener? or ?you?) (together, the ?Parties?). WHEREAS, Ms. Vakiener has served as the Chief Commercial Officer of the Company. And, WHEREAS the Chief Commercial Officer position has been eliminated by the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35945 EPIZYME, INC. (Exact name

First Amendment to the Companion Diagnostics Agreement dated October 23, 2013 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (23)

Exhibit 10.23 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COMPANION DIAGNOSTICS AGREEMENT This First Amendment (?Amendment?) shall be effective as of this 31st day of May 2013 (?Amendment Effective

Second Amendment to the Companion Diagnostics Agreement dated November 16, 2015 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (23)

Exhibit 10.24 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SECOND AMENDMENT TO COMPANION DIAGNOSTICS AGREEMENT This Second Amendment (?Second Amendment?) shall be effective as of this 16th day of November (?Amendment

Consulting Agreement, dated October 27, 2021, by and between the Registrant and Matthew Ros (23)

Exhibit 10.44 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is entered into as of October 27, 2021 by and between Epizyme, Inc. (the ?Company?), and Matthew Ros (?Mr. Ros? or ?you?) (together, the ?Parties?). WHEREAS, Mr. Ros has served as the Executive Vice President, Chief Strategy and Business Officer of the Company; WHEREAS the Executive Vice President, Chief Strategy and Bu

As filed with the Securities and Exchange Commission on March 1, 2022

As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.

Companion Diagnostics Agreement dated as of December 18, 2012 between the Registrant and Eisai Co., Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (23)

Exhibit 10.22 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION COPY 18th December 2012 COMPANION DIAGNOSTICS AGREEMENT BETWEEN EPIZYME, INC. and EISAI CO., LTD. on the one side AND ROCHE MOLECULAR SYSTEMS, INC.

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022

Exhibit 99.1 Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update TAZVERIK? (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into 3Q 2023 Company Engaged in Global Sta

Filing Fee Table Exhibit

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Epizyme, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number

Joint Filing Agreement

EX-99.1 2 tm226094d24ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001

EPZM / Epizyme Inc / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm226094d24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Epizyme, Inc (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropria

EPZM / Epizyme Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Epizyme Inc. Title of Class of Securities: Common Stock CUSIP Number: 29428V104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

EPZM / Epizyme Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Epizyme, Inc. (Name of Issuer) COM (Title of Class of Securities) 29428V104 (CUSIP Number) January 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

EPZM / Epizyme Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

SC 13G/A 1 epzma920822.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* Epizyme, Inc. (Name of Issuer) COM (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

EPZM / Epizyme Inc / HUTCHMED (China) Ltd - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Epizyme, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29428V 104 (CUSIP Number) Christian Hogg c/o HUTCHMED Group Investment Limited (formerly known as “Hutchison China MediTech Investment Limited”) Vistra Corporate Se

JOINT FILING AGREEMENT

EX-99.A 2 d661507dex99a.htm EXHIBIT A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(I) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to beneficial o

EPZM / Epizyme Inc / Rpi Finance Trust - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) George Lloyd, Esq. RP Management, LLC, 110 E. 59th Street, 33rd Floor New York, NY 10022 (212) 883-2280 (Name, Address and Telephone Number of Pe

56,666,667 Shares Epizyme, Inc. Common Stock $1.50 Per Share

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-255806 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 13, 2021) 56,666,667 Shares Epizyme, Inc. Common Stock $1.50 Per Share We are offering 56,666,667 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?EPZM.? The last reported sale price of our common stock on The

Underwriting Agreement, dated January 26, 2022, by and among the Company and Jefferies, LLC, as representative of the several Underwriters

EX-1.1 2 d301490dex11.htm EX-1.1 Exhibit 1.1 Execution Version 56,666,667 Shares Epizyme, Inc. Common Stock UNDERWRITING AGREEMENT January 26, 2022 JEFFERIES LLC As Representative of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Epizyme, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the sever

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Shares Epizyme, Inc. Common Stock $ Per Share

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-255806 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates — Preliminary TAZVERIK® (tazemetostat) Net Product Revenue Expected to be Between $11.2-11.7 Million and Between $30.6-31.1 Mill

Exhibit 99.1 Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates ? Preliminary TAZVERIK? (tazemetostat) Net Product Revenue Expected to be Between $11.2-11.7 Million and Between $30.6-31.1 Million for 4Q 2021 and Full-Year 2021, Respectively; Preliminary TAZVERIK Commercial Net Sales Expected to be Between $7.0-7.5 Million and B

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2021 EPIZYME, INC.

Epizyme Announces Updates to Its Board of Directors

Exhibit 99.1 Epizyme Announces Updates to Its Board of Directors CAMBRIDGE, Mass., November 18, 2021 ? Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company?s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number

License Agreement dated August 7, 2021 between the Registrant and Hutchison China MediTech Investment Limited (1)

Exhibit 10.6 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Execution Version LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) is made and entered into as of August 7, 2021 (?Effective Date?) between Epizyme,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Form of Restricted Stock Unit Agreement (Inducement Grant) (1)

Exhibit 10.2 EPIZYME, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (the ?Agreement?) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) Epizyme, Inc. (the ?Company?) has selected you to receive an award of restricted stock units (?RSUs?). The terms and conditions attached hereto are a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date (the ?Grant Date?): Num

Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update — TAZVERIK® (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% — — Received $25 Million Upfront Payment from HUTCHMED License Agreement — — S

Exhibit 99.1 Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update ? TAZVERIK? (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% ? ? Received $25 Million Upfront Payment from HUTCHMED License Agreement ? ? SYMPHONY-1 (EZH-302) Preparing for Phase 3 Initiation; SETD2 Phase 1/1b Study Initiated ? CAMBRIDGE, Mass., November 9, 2021 ? Epizyme (Na

Form of Stock Option Agreement (Inducement Grant) (1)

Exhibit 10.1 EPIZYME, INC. NON-QUALIFIED STOCK OPTION AGREEMENT Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) Epizyme, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Number of shares of the Company?s Common Stock subject to this optio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR f ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC.

Consulting Agreement dated August 4, 2021 between the Company and Robert B. Bazemore (1)

Exhibit 10.4 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is entered into as of August 4, 2021 by and between Epizyme, Inc. (the ?Company?), and Robert B. Bazemore (?Mr. Bazemore? or ?you?) (together, the ?Parties?). WHEREAS, Mr. Bazemore has delivered to the Company his resignation from his positions as President and Chief Executive Officer of the Company and from the Board of

Employment Offer Letter dated August 4, 2021 between the Company and Grant Bogle (1)

Exhibit 10.5 August 4, 2021 Grant Bogle c/o Epizyme, Inc. 400 Technology Square, 4th Floor Cambridge, MA 02139 Dear Grant: It is my pleasure to extend to you this offer of employment with Epizyme, Inc. (the ?Company?). On behalf of the Company, I am pleased to set forth below the terms of your employment with the Company: 1. Employment. You will be employed to serve on a full-time basis as an empl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

5,653,000 SHARES OF COMMON STOCK

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259680 PROSPECTUS 5,653,000 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, of up to 5,653,000 shares of common stock issuable upon exercise of a warrant previously issued by Epizyme, Inc. to the selling stockholder, Hutchison China MediTech Investment Limited, which we refer to as Hutchmed or

EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, MA 02139

EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, MA 02139 September 27, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Epizyme, Inc. Registration Statement on Form S-3 File No. 333-259680 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amend

As filed with the Securities and Exchange Commission on September 21, 2021

Table of Contents As filed with the Securities and Exchange Commission on September 21, 2021 Registration No.

Warrant to Purchase Stock, dated August 7, 2021, by and between the Registrant and Hutchison China MediTech Investment Limited

Exhibit 4.3 Execution Version Warrant THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND

[Signature page follows]

? Exhibit 99.1 ? Execution Version ? Warrant ? THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE?5 BELOW, MAY?NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID

EPZM / Epizyme Inc / HUTCHMED (China) Ltd - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Epizyme, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29428V 104 (CUSIP Number) Christian Hogg c/o Hutchison China MediTech Investment Limited Vistra Corporate Services Centre Wickhams Cay II, Road Town Tortola, VG1110

Agreement and Plan of Merger, dated as of June 27, 2022, by and among the Parent, the Purchaser and the Company (incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with the Securities and Exchange Commission on June 27, 2022)

Exhibit 10.1 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this ?Fifth Amendment?) is made as of August 11, 2021, by and between ARE-TECH SQUARE, LLC, a Delaware limited liability company (?Landlord?), and EPIZYME, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of June 15, 2012, as amended by that certain Firs

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Joint Filing Agreement

Exhibit 99.2 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of this statement on Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock, par value $0.0001 per share, of Epizyme, Inc., a Delaware corporation, and to th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

Certificate of Amendment of Restated Certificate of Incorporation of the Company, as amended. (1)

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EPIZYME, INC. Epizyme, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: That the name of the Corporation is Epizyme, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZV

Exhibit 99.1 Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK? Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK? and Focus Investment on Important Value-Driving Programs IND Clearance for Novel SETD2 Inhibitor, EZM-0414; Clinical Trial Initiati

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, MA 02139

CORRESP 1 filename1.htm EPIZYME, INC. 400 Technology Square, 4th Floor Cambridge, MA 02139 May 11, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Epizyme, Inc. Registration Statement on Form S-3 File No. 333-255806 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act

Form of Stock Option Agreement under 2013 Stock Incentive Plan (1)

Exhibit 10.1 EPIZYME, INC. STOCK OPTION AGREEMENT Epizyme, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2013 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Incentive Stock Option or Non-Qualified Stock Option: Number of shares of the Company?s Common Stock subj

Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Canc

Exhibit 99.1 Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK? Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigational New Drug (IND) Submission for Novel SETD2 Inhibitor Progr

Form of Subordinated Indenture

Exhibit 4.4 EPIZYME, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplic

- S-3

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2021 Registration No.

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (1)

Exhibit 10.2 EPIZYME, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (the ?Agreement?) Epizyme, Inc. (the ?Company?) has selected you to receive an award of restricted stock units (?RSUs?) pursuant to the Company?s 2013 Stock Incentive Plan (the ?Plan?). The terms and conditions attached hereto are also a part hereof. Terms used in this Agreement which are not defined in this Agreement shall have the

Form of Senior Indenture

Exhibit 4.3 EPIZYME, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicable 31

Form of Subordinated Note

Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Open Market Sale AgreementSM, dated May 6, 2021, by and between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM May 6, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Epizyme, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, par val

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

Form of Senior Note

Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

definitive proxy statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

- PRE 14A

PRE 14A 1 d839557dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35945 EPIZYME, INC. (Exact name

Amended and Restated Loan Agreement dated as of November 3, 2020 by and among the Registrant and BioPharma Credit Investments V (Master) LP, BPCR Limited Partnership and BioPharma Credit PLC (25)

Exhibit 10.39 Execution Version AMENDED AND RESTATED LOAN AGREEMENT Dated as of November 3, 2020 among EPIZYME, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR LIMITED PARTNERSHIP (as a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) AMENDED AND RESTATED LOAN AGREEMENT THIS AMENDED AND RESTATED LOAN AGREEMENT (this ?Agreement?), dated as of November 3, 202

Amended and Restated Collaboration and License Agreement dated as of March 12, 2015, by and between the Registrant and Eisai Co. Ltd. (25)

Exhibit 10.24 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EISAI CO., LTD. and EPIZYME, INC. CONFIDENTIAL Table of Contents Page ARTIC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Numb

CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK® Net Revenues of $4.5 Million for 4Q 2020; $11.5 M

Exhibit 99.1 CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK? Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK? in ES and FL and Phase 1b Portion of Phase 1b/2 Castration-R

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2021 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number

Non-Employee Director Compensation Program, effective January 1, 2021 (17)

Exhibit 10.26 EPIZYME, INC. Non-Employee Director Compensation Program Under Epizyme, Inc.?s (the ?Company?) non-employee director compensation program, the Company pays its non-employee directors retainers in cash. Each non-employee director receives a cash retainer for service on the Company?s board of directors (the ?Board?) and for service on each committee on which the director is a member, a

- S-8

S-8 1 d96543ds8.htm S-8 As filed with the Securities and Exchange Commission on February 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Epizyme, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1349956 (State or other jurisdiction of incorporation or organiz

Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety

Exhibit 99.1 Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK? Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK? in ES and FL and Phase 2 Castration-Resistant Prostate Cancer Fully Enrolled; Initial

Employment Offer Letter between the Company and Victoria Vakiener, dated October 23, 2018 (25)

Exhibit 10.16 October 23, 2018 Victoria Vakiener (Delivered via email) Dear Vicki: It is my pleasure to extend to you this offer of employment with Epizyme, Inc. (the ?Company?). On behalf of the Company, I am pleased to set forth below the terms of your employment with the Company: 1. Employment. You will be employed to serve on a full-time basis as the Company?s Senior Vice President, Commercial

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of Epizyme, Inc., which

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Epizyme, Inc (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Epizyme, Inc (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Epizyme, Inc. (Name of Issuer) (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Epizyme Inc. Title of Class of Securities: Common Stock CUSIP Number: 29428V104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

Termination of a Material Definitive Agreement - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2020 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2020 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (E

Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Company Reports 55% Growth in Net Revenues of TAZVERIK® Compared with 2Q 2020 Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Gro

EX-99.1 Exhibit 99.1 Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Company Reports 55% Growth in Net Revenues of TAZVERIK® Compared with 2Q 2020 Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023 On-Track to Initiate Efficacy Portions of Confirmatory Trials in E

Amendment No. 2 to Collaboration Agreement dated September 17, 2020 by and between the Company and Boehringer Ingelheim International GmbH. (1)

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Amendment No. 2 to Collaboration Agreement This Amendment No. 2 (“Amendment 2”) is made and entered into as of September 17, 2020 (“Amendment 2 Effective Date”) by an

EPZM / Epizyme, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

Restated Certificate of Incorporation of the Company, as amended (1)

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EPIZYME, INC. Epizyme, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: That the name of the Corporation is Epizyme, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State

Epizyme Reports Business Progress and Second Quarter 2020 Financial Results TAZVERIK® Approved for Multiple Cancer Indications; Executing Well on Commercial Launches for TAZVERIK in Epithelioid Sarcoma and Follicular Lymphoma Conference Call to be He

EX-99.1 Exhibit 99.1 Epizyme Reports Business Progress and Second Quarter 2020 Financial Results TAZVERIK® Approved for Multiple Cancer Indications; Executing Well on Commercial Launches for TAZVERIK in Epithelioid Sarcoma and Follicular Lymphoma Conference Call to be Held Today, August 4 at 8:30 a.m. ET CAMBRIDGE, Mass., Aug. 4, 2020 – Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2020 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2020 EPIZYME, INC.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

2013 Stock Incentive Plan, as amended on March 24, 2020 (Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35945) on May 4, 2020 and incorporated herein by reference)

Exhibit 10.2 EPIZYME, INC. 2013 STOCK INCENTIVE PLAN 1.Purpose The purpose of this 2013 Stock Incentive Plan (the “Plan”) of Epizyme, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such p

Amendment to Collaboration Agreement dated March 10, 2020 by and between the Company and Boehringer Ingelheim International GmbH. (1)

Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Amendment No. 1 to Collaboration Agreement This Amendment No. 1 (“Amendment 1”) is made and entered into as of March 10, 2020 (“Amendment 1 Effective Date”) by and be

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2020 EPIZYME, INC.

Epizyme Reports Business Progress and First Quarter 2020 Financial Results TAZVERIK™ Successfully Launched for First Approved Indication; PDUFA Date of June 18, 2020 for sNDA for Follicular Lymphoma Indication Business Continuity Plans in Place in Re

EX-99.1 Exhibit 99.1 Epizyme Reports Business Progress and First Quarter 2020 Financial Results TAZVERIK™ Successfully Launched for First Approved Indication; PDUFA Date of June 18, 2020 for sNDA for Follicular Lymphoma Indication Business Continuity Plans in Place in Response to COVID-19 Conference Call to be Held Today, May 4 at 9:00 a.m. ET CAMBRIDGE, Mass., May 4, 2020 – Epizyme, (Nasdaq: EPZM

Employment Offer Letter between the Company and Jeffery Kutok, dated February 21, 2020. (1)

EX-10.1 2 epzm-ex101275.htm EX-10.1 Exhibit 10.1 February 21, 2020 Mr. Jeffery Kutok (delivered via email) Dear Jeffery: It is my pleasure to extend to you this offer of employment with Epizyme, Inc. (the “Company”). I am pleased to set forth below the terms of your employment with the Company: 1. Employment. You will be employed to serve on a full-time basis as the Company’s Chief Scientific Offi

EPZM / Epizyme, Inc. DEFA14A - - DEFA14A

DEFA14A 1 d834684ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox

EPZM / Epizyme, Inc. DEF 14A - - DEF 14A

DEF 14A 1 epzm-def14a20200529.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary

EPZM / Epizyme, Inc. PRE 14A - - PRE 14A

PRE 14A 1 epzm-pre14a20200529.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2020 EPIZYME, INC.

Purchase Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (15)

Exhibit 10.45 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Purchase Agreement by and between Epizyme, Inc. and RPI Finance Trust Dated as of November 4, 2019 SECTION 1 Defined Terms and Rules of Constructio

Exhibit 4.4

EXHIBIT 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.0001 per share (the “Common Stock”) of Epizyme, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is intended as a sum

As filed with the Securities and Exchange Commission on February 27, 2020

As filed with the Securities and Exchange Commission on February 27, 2020 Registration No.

Warrant Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (15)

Exhibit 10.46 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURIT

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35945 EPIZYME, INC. (Exact name

Guaranty and Security Agreement dated as of November 18, 2019 by and between the Registrant and BioPharma Credit PLC (15)

Exhibit 10.44 Execution Version GUARANTY AND SECURITY AGREEMENT Dated as of November 18, 2019 by EPIZYME, INC. (as Borrower), and Each OTHER Grantor From Time to Time Party Hereto in favor of BIOPHARMA CREDIT PLC (as Collateral Agent on behalf of Lenders and the other Secured Parties) TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS Section 1.1. Definitions 1 Section 1.2. Certain Other Terms 5 ARTIC

Loan Agreement dated as of November 4, 2019 by and between the Registrant and BioPharma Credit Investments V (Master) LP and BioPharma Credit PLC (25)

Exhibit 10.43 EXECUTION VERSION LOAN AGREEMENT Dated as of November 4, 2019 among EPIZYME, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”), dated as of November 4, 2019 (the “Execution Date”) by and among EPIZYME, INC., a Delaware corporation (as “Borrower

Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results TAZVERIK™ (tazemetostat) Commercial Launch Underway for Epithelioid Sarcoma TAZVERIK sNDA for Follicular Lymphoma Accepted for Filing by FDA with Priorit

EX-99.1 Exhibit 99.1 Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results TAZVERIK™ (tazemetostat) Commercial Launch Underway for Epithelioid Sarcoma TAZVERIK sNDA for Follicular Lymphoma Accepted for Filing by FDA with Priority Review; PDUFA Target Action Date of June 18, 2020 Expanding Future TAZVERIK Value through Clinical Development into New Combina

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2020 EPIZYME, INC.

EPZM / Epizyme, Inc. / Rpi Finance Trust - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) George Lloyd, Esq. RP Management, LLC, 110 E. 59th Street, 33rd Floor New York, NY 10022 (212) 883-2280 (Name, Address and Telephone Number of Pe

EPZM / Epizyme, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Epizyme, Inc (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Epizyme, Inc., which

EPZM / Epizyme, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment

SC 13G/A 1 a20-611819sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Epizyme, Inc. (Name of Issuer) Common (Title of Class of Securities) 29428V104 (CUSIP Nu

EPZM / Epizyme, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Epizyme Inc Title of Class of Securities: Common Stock CUSIP Number: 29428V104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(

EPZM / Epizyme, Inc. / Celgene European Investment Co LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EPIZYME, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value Additional Capital Further Extends Company’s Operating Runway into 2022 Commercially Prepared to Launch Tazemetostat for

EX-99.1 Exhibit 99.1 Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value Additional Capital Further Extends Company’s Operating Runway into 2022 Commercially Prepared to Launch Tazemetostat for Epithelioid Sarcoma; PDUFA Date Set for January 23, 2020 CAMBRIDGE, Mass., Jan. 6, 2020 — Epizyme, Inc. (Nasdaq: EPZM), a late-s

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2019 EPIZYME, INC.

EPZM / Epizyme, Inc. / Rpi Finance Trust - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) George Lloyd, Esq. RP Management, LLC, 110 E. 59th Street, 33rd Floor New York, NY 10022 (212) 883-2280 (Name, Address and Telephone Number of Perso

WARRANT TO PURCHASE STOCK Company: EPIZYME, INC., a Delaware corporation (the “Company”) Number of Shares: 2,500,000, subject to adjustment in accordance with Article 2 below Class of Stock: Common Stock of the Company, par value $0.0001 per share (t

EX-99.B Exhibit B THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SEC

JOINT FILING AGREEMENT

EX-99.A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(I) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule I3D (including amendments thereto) with respect to beneficial ownership of shares of Common S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2019 EPIZYME, INC.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (E

Fourth Amendment to the Companion Diagnostics Agreement dated July 26, 2019 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. and Roche Sequencing Solutions, Inc. on the other side. (1)

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. FOURTH AMENDMENT TO COMPANION DIAGNOSTICS AGREEMENT This Fourth Amendment (“Fourth Amendment”) shall be effective as of this 26 day of July, 2019 (“Amendment Effectiv

Lease Agreement dated as of August 16, 2019 by and between Epizyme, Inc. and BMR-Hampshire LLC. (1)

EX-10.1 2 epzm-ex101360.htm EX-10.1 Exhibit 10.1 LEASE by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company and EPIZYME, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 4 4. Possession and Commencement Date 4 5. Condition of Premises 6 6. Rentable Area 6 7. Rent 7 8. Rent Adjustments 8 9. Operating Expenses 8 10. Taxes on

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2019 EPIZYME, INC.

Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH

EX-99.1 Exhibit 99.1 Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2019 Updated Phase 2 Follicular Lymphoma Data Selected for Oral Pre

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2019 EPIZYME, INC.

Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

EX-99.1 Exhibit 99.1 Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth CAMBRIDGE, Mass., Sept. 4, 2019 — Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development executive, Victoria Richon, Ph.D.,

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2019 EPIZYME, INC.

Epizyme Reports Business Progress and Second Quarter 2019 Results Tazemetostat NDA Submission Accepted for Priority Review for Epithelioid Sarcoma Industry Veteran Paolo Tombesi Appointed as Chief Financial Officer

EX-99.1 Exhibit 99.1 Epizyme Reports Business Progress and Second Quarter 2019 Results Tazemetostat NDA Submission Accepted for Priority Review for Epithelioid Sarcoma Industry Veteran Paolo Tombesi Appointed as Chief Financial Officer CAMBRIDGE, Mass., Aug. 9, 2019 – Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2019 EPIZYME, INC.

Non-Employee Director Compensation Program.(1)

Exhibit 10.2 EPIZYME, INC. Non-Employee Director Compensation Program Under Epizyme, Inc.’s (the “Company”) director compensation program, the Company pays its non-employee directors retainers in cash. Each non-employee director receives a cash retainer for service on the board of directors and for service on each committee on which the director is a member, as well as additional fees for service

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35945 EPIZYME, INC. (Exact

Employment Offer Letter between the Company and Paolo Tombesi, dated July 1, 2019.(1)

Exhibit 10.1 July 1, 2019 Mr. Paolo Tombesi (delivered via email) Dear Paolo: It is my pleasure to extend to you this offer of employment with Epizyme, Inc. (the “Company”). I am pleased to set forth below the terms of your employment with the Company: 1. Employment. You will be employed to serve on a full-time basis as the Company’s Chief Financial Officer, commencing on a date on or around Augus

Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer

EX-99.1 Exhibit 99.1 Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer CAMBRIDGE, Mass., July 22, 2019 — Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019. Mr. Tombesi brings over 30 years of exte

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 d744262d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2019 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation) (Com

EPZM / Epizyme, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOC. 13, LP - EPIZYME, INC. -- SCHEDULE 13D/A (#3E) Activist Investment

SC 13D/A 1 epizyme-sch13d18327.htm NEW ENTERPRISE ASSOC. 13, LP - EPIZYME, INC. - SCHEDULE 13D/A (#3E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Epizyme, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 29428V104 (CUSIP Number) Louis S. Citron, Esq. New Enterpr

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2019 EPIZYME, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2019 EPIZYME, INC.

Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively Updated Data from Tazemet

EX-99.1 Exhibit 99.1 Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively Updated Data from Tazemetostat Development Program to be Presented in the Second Quarter First Research Milestone Achieved in Worldwide Collaboration with

Quarterly Report - 10-Q

10-Q 1 epzm-10q20190331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

EPZM / Epizyme, Inc. DEFA14A

DEFA14A 1 d684860ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox

EPZM / Epizyme, Inc. DEF 14A

DEF 14A 1 d684860ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Series A Convertible Pre

424(b)(5) Table of Contents CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Series A Convertible Preferred Stock, par value $0.

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, par value

424B5 1 d655178d424b5.htm 424(B)(5) Table of Contents CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, par value $0.0001 per share 11,500,000 $11.50 $132,250,000 $16,028.70 (1) Assumes exercise in full of the

Certificate of Designation of Series A Convertible Preferred Stock of the Company

EX-3.1 Exhibit 3.1 EPIZYME, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW EPIZYME, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accorda

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2019 EPIZYME, INC.

Form of Series A Preferred Stock Certificate

EX-4.1 Exhibit 4.1 PA- ** Shares Series A Preferred Stock EPIZYME, INC. A Delaware Corporation THIS CERTIFIES THAT ** is the record holder of ** shares of Series A Convertible Preferred Stock of Epizyme, Inc. transferable only on the books of the Corporation by the holder, in person, or by duly authorized attorney, upon surrender of this certificate properly endorsed or assigned. This certificate

Underwriting Agreement related to the Preferred Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company, as representatives of the several Underwriters

EX-1.2 Exhibit 1.2 304,348 Shares Epizyme, Inc. Series A Convertible Preferred Stock UNDERWRITING AGREEMENT March 6, 2019 JEFFERIES LLC CITIGROUP GLOBAL MARKETS INC. COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company,

Underwriting Agreement related to the Common Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company, as representatives of the several Underwriters

EX-1.1 Exhibit 1.1 Execution Version 10,000,000 Shares Epizyme, Inc. Common Stock UNDERWRITING AGREEMENT March 6, 2019 JEFFERIES LLC CITIGROUP GLOBAL MARKETS INC. COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LL

Shares Epizyme, Inc. Series A Convertible Preferred Stock $ Per Share

424B5 1 d720886d424b5.htm 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-224159 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompan

Shares Epizyme, Inc. Common Stock $ Per Share

424B5 1 d655178d424b5.htm 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-224159 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompan

Other Events

8-K 1 d718025d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2019 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporat

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d708916d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2019 EPIZYME, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35945 26-1349956 (State or Other Jurisdiction of Incorporation)

Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019 Productive FDA Meeting Supports Planned Acc

EX-99.1 Exhibit 99.1 Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019 Productive FDA Meeting Supports Planned Accelerated Approval Submission for Relapsed/Refractory Follicular Lymphoma Patients with or without EZH2 Mutations Operating Runway

EPZM / Epizyme, Inc. S-8

S-8 1 d650414ds8.htm S-8 As filed with the Securities and Exchange Commission on February 26, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Epizyme, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1349956 (State or other jurisdiction of incorporation or organi

Collaboration Agreement dated as of November 14, 2018 by and between the Registrant and Boehringer Ingelheim International GmbH (21)

Exhbit 10.39 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATION AGREEMENT between BOEHRINGER INGELHEIM INTERNATIONAL GmbH and EPIZYME, INC. Dated as of Wednesday November 14, 2018 BII Contract Number [**] TABLE OF CONTENTS Page ARTICLE 1 Definitions 1 ARTICLE 2 Collaboration Management 27 2.1. Joint Stee

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (21)

Exhibit 10.9 EPIZYME, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”) Epizyme, Inc. (the “Company”) has selected you to receive an award of restricted stock units (“RSUs”) pursuant to the Company’s 2013 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Terms used in this Agreement which are not defined in this Agreement shall have the

EPZM / Epizyme, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35945 EPIZYME, INC. (Exact name

Non-Employee Director Compensation Program (21)

Exhibit 10.27 EPIZYME, INC. Non-Employee Director Compensation Program Under Epizyme, Inc.’s (the “Company”) director compensation program, the Company pays its non-employee directors retainers in cash. Each non-employee director receives a cash retainer for service on the board of directors and for service on each committee on which the director is a member, as well as additional fees for service

Executive Severance and Change in Control Plan (21)

Exhibit 10.11 EPIZYME, INC. Severance and Change in Control Plan (as amended through January 24, 2019) Section I: Establishment and Purpose of Plan Epizyme, Inc. (the “Company”) hereby establishes an unfunded Severance and Change in Control Plan (the “Plan”), which is intended to be a welfare benefit plan within the meaning of Section 3(1) of the Employee Retirement Income Security Act of 1974, as

EPZM / Epizyme, Inc. / KLEINER PERKINS CAUFIELD & BYERS XIII, LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statemen

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Epizyme, Inc, which m

EPZM / Epizyme, Inc. / Palo Alto Investors, LLC - SC 13G/A Passive Investment

SC 13G/A 1 Epizyme13GA4.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

EPZM / Epizyme, Inc. / Redmile Group, LLC - SCHEDULE 13G Passive Investment

SC 13G 1 tv513369sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Epizyme, Inc (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

EPZM / Epizyme, Inc. / VANGUARD GROUP INC Passive Investment

epizymeinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Epizyme Inc Title of Class of Securities: Common Stock CUSIP Number: 29428V104 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate